These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 23278696)

  • 21. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
    Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
    Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats.
    Onoue M; Kurita A; Kado S; Matsumoto T; Kaneda N; Uchida K; Kato I; Yokokura T
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):595-605. PubMed ID: 17549477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of breast cancer resistance protein inhibitors and pharmaceutical excipients on decreasing gastrointestinal toxicity of camptothecin analogs.
    Zhang XX; Pan WS; Gan L; Zhu CL; Gan Y
    Acta Pharmacol Sin; 2008 Nov; 29(11):1391-8. PubMed ID: 18954535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
    Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
    Clin Pharmacol Ther; 2002 Sep; 72(3):265-75. PubMed ID: 12235447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver.
    Tobin PJ; Hong Y; Seale JP; Rivory LP; McLachlan AJ
    J Pharm Pharmacol; 2005 Jan; 57(1):39-45. PubMed ID: 15638991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of multiple dose activated charcoal on the disposition kinetics of irinotecan in rats.
    Balram C; Zhou QY; Cheung YB; Lee EJ
    Drug Metabol Drug Interact; 2002; 19(2):137-48. PubMed ID: 12751911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats.
    Hu Z; Yang X; Ho PC; Chan E; Chan SY; Xu C; Li X; Zhu YZ; Duan W; Chen X; Huang M; Yang H; Zhou S
    Pharm Res; 2005 Jun; 22(6):902-14. PubMed ID: 15948034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
    Arimori K; Kuroki N; Hidaka M; Iwakiri T; Yamsaki K; Okumura M; Ono H; Takamura N; Kikuchi M; Nakano M
    Pharm Res; 2003 Jun; 20(6):910-7. PubMed ID: 12817897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
    Ikuno N; Soda H; Watanabe M; Oka M
    J Natl Cancer Inst; 1995 Dec; 87(24):1876-83. PubMed ID: 7494232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.
    Takasuna K; Kasai Y; Kitano Y; Mori K; Kobayashi R; Hagiwara T; Kakihata K; Hirohashi M; Nomura M; Nagai E
    Jpn J Cancer Res; 1995 Oct; 86(10):978-84. PubMed ID: 7493918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
    Gupta E; Lestingi TM; Mick R; Ramirez J; Vokes EE; Ratain MJ
    Cancer Res; 1994 Jul; 54(14):3723-5. PubMed ID: 8033091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adsorption of irinotecan onto oral adsorbent AST-120 (Kremezin) for preventing delayed diarrhea.
    Hidaka M; Yamasaki K; Okumura M; Ogikubo T; Iwakiri T; Setoguchi N; Nishida K; Nagai K; Ikenoue T; Arimori K
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):321-8. PubMed ID: 16770581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Panipenem does not alter the pharmacokinetics of the active metabolite of irinotecan SN-38 and inactive metabolite SN-38 glucuronide (SN-38G) in rats.
    Kato A; Ueyama J; Abe F; Hotta K; Tsukiyama I; Oshima T; Kondo F; Saito H; Hasegawa T
    Anticancer Res; 2011 Sep; 31(9):2915-22. PubMed ID: 21868538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride.
    Fujita D; Saito Y; Nakanishi T; Tamai I
    Drug Metab Dispos; 2016 Jan; 44(1):1-7. PubMed ID: 26526067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT.
    Kurita A; Kaneda N
    J Chromatogr B Biomed Sci Appl; 1999 Mar; 724(2):335-44. PubMed ID: 10219676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous administration of irinotecan elevates the blood beta-glucuronidase activity in rats.
    Kaneda N; Kurita A; Hosokawa Y; Yokokura T; Awazu S
    Cancer Res; 1997 Dec; 57(23):5305-8. PubMed ID: 9393754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Function of multidrug resistance-associated protein 2 in acute hepatic failure rats.
    Yokooji T; Murakami T; Yumoto R; Nagai J; Takano M
    Eur J Pharmacol; 2006 Sep; 546(1-3):152-60. PubMed ID: 16899240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dramatic increase in hepatic and biliary curcumin exposure by modulation of its elimination pathway in rats.
    Lee JH; Kim HG; Oh JH; Lee YJ
    J Pharm Pharmacol; 2013 Mar; 65(3):423-9. PubMed ID: 23356851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites.
    Mallants R; Van Oosterwyck K; Van Vaeck L; Mols R; De Clercq E; Augustijns P
    Xenobiotica; 2005; 35(10-11):1055-66. PubMed ID: 16393861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of orally administered camptothecins.
    Gupta E; Vyas V; Ahmed F; Sinko P; Cook T; Rubin E
    Ann N Y Acad Sci; 2000; 922():195-204. PubMed ID: 11193895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.